Gansulin is a brand under Tonghua Dongbao Group Co., Ltd. and an insulin brand. The marketing headquarters is located in Beijing, China. Ganshulin insulin preparations and raw materials have passed the export certification in 15 countries, and its partners are located in Europe, Asia, Africa and the Americas. At present; factories have been built in six countries in Bangladesh, Iran, Ukraine, Poland, Sweden and Malaysia. It is a Chinese company focusing on the development of insulin.

In December 1992, China Tonghua Dongbao Group was established. During this period, several enterprises were merged, especially in 1992, Hengde Village, Ermi Town, Tonghua County, where the group was located, which created the first typical example of "using enterprises to combine agriculture" in China, which caused a strong response across the country. In the 13 years since the establishment of the group, the company has developed rapidly in scale, the wide range of diversified projects, the number of mergers of state-owned private enterprises, the leading production equipment and process flow, and the high level of research in the scientific research team are all called miracles of domestic enterprises' development. Industry insiders praised it as the "Dongbao Model", creating a myth of the booming development of Chinese companies.

Dongbao's pharmaceutical industry has attracted worldwide attention for its world-renowned biopharmaceutical technology. A large number of new drugs and flagship products have been developed and launched, such as "Zhennaoping", Dongbaogantai Tablets, and Naoxuekang Tablets. In the field of biopharmaceuticals, the group has invested hundreds of millions of scientific research funds and successfully developed the high-tech preparation drug "Gan Shulin" with China's independent intellectual property rights in 1998, making China the third in the world to produce genes after the United States and Denmark. Recombinant human insulin, the second country that can produce insulin glargine. Dongbao Group has become one of the world's most substantial human insulin production bases with today's technology.